Inspire2Live
  • Home
  • About us
    • The patient’s voice
      • Origin story of Inspire2live
      • Mission & vision
      • How we work
      • Partners
      • This is how we spend our money
      • Organisation
    • Patient Advocacy
      • What is patient advocacy?
      • Meet our patient advocates
      • In memoriam
    • Contact
      • Find us on social media
      • Contact details Inspire2live
      • Annual Reports
      • For the media
      • Get in contact
  • Our work
    • Our projects
      • DEEP Diagnostics
      • HPV Related Cancer
      • Cancer Registries
      • Discover all our projects
    • Congresses
      • Upcoming congresses
      • Annual congresses
      • Past congresses
    • World Campus
      • About the World Campus
      • Lectures & sessions
      • Discover our campus
  • Our impact
    • Achievements
    • Research & development
    • Access and implementation
  • News & media
  • Join Inspire2live
  • Donate
Select Page
Home > News & media > In the media > Personalized Treatment for Hematologic Diseases in Europe: An EHA Position Paper
Personalized Treatment for Hematologic Diseases in Europe: An EHA Position Paper
March 29, 2021

https://journals.lww.com/hemasphere/Fulltext/2020/10000/Personalized_Treatment_for_Hematologic_Diseases_in.8.aspx

More news

What about Post-Corona

August 12th, 2021

READ MORE

Awareness, Education, Prevention and Government

August 12th, 2021

READ MORE

Quality of life for the global patient

August 12th, 2021

READ MORE

Navigation

Home

The patient’s voice

Patient advocacy

World Campus

Our impact

Research & development

More Inspire2Live

Our mission & vision

How we work

Partners

Congresses

News & media

ANBI statement

Join us

Donate

As a company

Become a patient advocate

Become a partner

Contact us

Follow on social media



Facebook



Twitter



LinkedIn



YouTube



Instagram

Disclaimer | Privacy statement | Cookie statement | ANBI number: 8220 32 752
Disclaimer | Privacy statement | Cookie statement | ANBI number: 8220 32 752